Oral deferiprone for iron chelation in people with thalassaemia

Background Thalassaemia major is a genetic disease characterised by a reduced ability to produce haemoglobin. Management of the resulting anaemia is through red blood cell transfusions. Repeated transfusions result in an excessive accumulation of iron in the body (iron overload), removal of which is...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cochrane database of systematic reviews 2013-08, Vol.2013 (8), p.CD004839
Hauptverfasser:	Fisher, Sheila A, Brunskill, Susan J, Doree, Carolyn, Chowdhury, Onima, Gooding, Sarah, Roberts, David J
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral BLOOD Blood disorders Chelation Therapy Chelation Therapy - adverse effects Child health Costs Deferiprone Deferoxamine Deferoxamine - adverse effects Deferoxamine - therapeutic use Genetic disorders HAEMOGLOBINOPATHIES Humans Insurance medicine Iron Chelating Agents Iron Chelating Agents - adverse effects Iron Chelating Agents - therapeutic use IRON CHELATION Iron Overload Iron Overload - drug therapy Iron Overload - etiology Medicine General & Introductory Medical Sciences Pyridones Pyridones - adverse effects Pyridones - therapeutic use Randomized Controlled Trials as Topic THALASSAEMIA Thalassemia Thalassemia - therapy TREATMENT Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!